Twitter | Search | |
Kiran Devisetty, MD
Radiation Oncologist, KCI McLaren Flint; Medical Director, Karmanos Cancer Network Rad Onc Research; Clinical Associate (MSU, CMU) & Assistant (WSU) Professor
216
Tweets
494
Following
380
Followers
Tweets
Kiran Devisetty, MD Jan 14
Important 5Y PRO QOL prospective data in with contemporary surgery and RT for . EBRT not different than AS in GU, GI, and ED tox for favorable risk; surgery worse GU & ED tox for unfavorable risk. Not surprised.
Reply Retweet Like
Kiran Devisetty, MD Jan 13
Fantastic and practical article on testosterone recovery in patients receiving . Patients likely assume recovery, but obviously not the case, and this provides data to help set expectations for such a huge QOL endpoint.
Reply Retweet Like
Kiran Devisetty, MD Jan 11
Proud to report continues to be ranked in top 5 out of LAPS in 2019 accruals (and top 10 overall) for 4 years running. Synergy between Downtown and Network continues to expand access to clinical trials in Michigan's largest cancer system.
Reply Retweet Like
Kiran Devisetty, MD retweeted
Rahul Tendulkar Jan 10
Social media is not where arguments can be “won” IMO - but much (reputation, credibility, friends) can be lost. SM can be useful to share dialogue & open eyes & minds to new ideas. Focus on the ideal future state & use SM to engage in productive ways to influence that change.
Reply Retweet Like
Kiran Devisetty, MD Jan 8
A priori would have thought intensive post hospital discharge resources would decrease re-admission, but apparently not. Just another example of the power of RCT's and that promising single institutional data must always be validated.
Reply Retweet Like
Kiran Devisetty, MD Jan 4
Wholeheartedly agree, but unfortunately difficult to address in the era of corporate medicine in which the emphasis seems to be more on maximizing throughput as opposed to thoroughness.
Reply Retweet Like
Kiran Devisetty, MD Jan 1
Decent and balanced overview of H&N cancer; fails to mention ORATOR, but does warn about de-escalation of treatment for positive outside of clinical trial.
Reply Retweet Like
Kiran Devisetty, MD Dec 30
Interesting point-counterpoint discussion on future of in era of immunotherapy. As highlighted at ASTRO, we need to keep asking the right questions and find answers that demonstrate synergy between the two.
Reply Retweet Like
Kiran Devisetty, MD Dec 26
Replying to @KiranDevisetty
Editorial said it best: "Ultimately, the paradox lies in... insurance companies increasingly require more evidence to prove... value and cost-effectiveness... before paying for it yet often deny coverage for patients who are randomly assigned to proton therapy in clinical trials"
Reply Retweet Like
Kiran Devisetty, MD Dec 26
More fodder for the fire of proton therapy vs. photon therapy? Nice, large comparative effectiveness study, but of course with all the usual caveats and will not quiet insurance demands for RCT's.
Reply Retweet Like
Kiran Devisetty, MD Dec 10
Practical guideline synopsis in for many of our cancer patients on narcotics. Sometimes it is the smallest of interventions that can have a significant impact on their quality of life...
Reply Retweet Like
Kiran Devisetty, MD Dec 6
Beginning of RT Oncotype? Beyond whole breast RT vs. No RT, will need validation on RNI vs. No RNI. Numbers small as only 10/356 pts with regional recurrence, but nice that authors able to classify 85% in axilla (i.e. not SCV).
Reply Retweet Like
Kiran Devisetty, MD retweeted
Sabin Motwani Dec 6
Long awaited RAPID and NSABP B-39/RTOG 0413 partial breast vs whole breast RCTs published in today. RAPID: NSABP B-39/RTOG 0413: Editorial: cc:
Reply Retweet Like
Kiran Devisetty, MD Dec 6
The Administrative Health Care Crisis
Reply Retweet Like
Kiran Devisetty, MD Dec 5
Well timed piece on the Administrative Health Care Crisis in which the US "pays about $500 billion in administrative costs for health care, that is, for things like billing and insurance overhead, not for actual medical care"
Reply Retweet Like
Kiran Devisetty, MD Dec 4
"The number of non-doctor workers in the health industry has exploded in the last two decades. The majority of these jobs aren’t clinical roles, like registered nurses. They are mostly administrative and management jobs". THAT is where cost cutting has to start.
Reply Retweet Like
Kiran Devisetty, MD Dec 4
Replying to @AKesarwala
It seemed that with any person he met, he always left a lasting impression. I only met him once, but still vividly remember his enthusiasm to be contrary.
Reply Retweet Like
Kiran Devisetty, MD Dec 4
Beautiful piece on importance of history of medicine & of Osler who "nurtured the notion of the medical profession as a global force for human betterment." Especially relevant in these turbulent times of healthcare reform
Reply Retweet Like
Kiran Devisetty, MD retweeted
Radiation Research Society Dec 4
Reply Retweet Like
Kiran Devisetty, MD Dec 3
Yet another (but larger) Single vs. Multi Fx study. Despite [barely] lack of non-inferiority in main endpoint (ambulation @ 8 wks), all secondary endpoints not dissimilar, thus not truly eliminating 8 Gy x1 in this pt population (way too many -'s).
Reply Retweet Like